Daprodustat —An HIF-PHI Inhibitor: The First Oral Medication for the Treatment of Anemia in Dialysis
Approximately 800,000 Americans have end stage kidney disease (ESKD).1 The kidney is a major organ responsible for producing erythropoietin (EPO) that led to red blood cells production.2 People dependent on dialysis do not produce adequate EPO, which leads to anemia.2 Anemia is common in chronic kidney disease (CKD) and affects almost all patients with ESKD.2 Before the availability of erythropoiesis-stimulating agents (ESA) medications, people with ESKD experienced anemia and often required blood transfusion.
Source: The Journal for Nurse Practitioners - Category: Nursing Authors: Timothy Nguyen Tags: Prescription Pad Source Type: research
More News: Anemia | Blood Transusion | Chronic Kidney Disease | Dialysis | Nurses | Nursing | Urology & Nephrology